Skip to main content

Table 5 Characteristics of biomarkers in four imaging-based clusters

From: Imaging-based clusters in current smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)

 

Cluster 1

Cluster 2

Cluster 3

Cluster 4

P value

 

N = 92

N = 45

N = 87

N = 55

 

Blood/serum biomarkers

 RBC distribution width (%)

14.25

(1.17)

14.04

(0.87)

13.63

(0.84)

14.13

(1.19)

0.0016

 Total WBC count (N/μl)

7153.15

(2290.62)

7352.89

(2527.31)

7109.77

(1954.51)

7073.09

(2122.85)

0.924

 Neutrophils% (%)

58.06

(9.52)

58.24

(11.78)

58.06

(9.65)

61.14

(10.22)

0.26

 Lymphocyte% (%)

31.35

(8.09)

31.39

(10.45)

30.81

(8.58)

27.74

(9.53)

0.088

 Monocyte% (%)

7.3

(2.5)

7.46

(2.12)

7.67

(2.18)

7.85

(2.2)

0.512

 Eosinophils% (%)

2.63

(1.64)

2.29

(1.74)

2.72

(1.75)

2.61

(1.9)

0.6

 Basophils% (%)

0.71

(0.61)

0.52

(0.36)

0.62

(0.54)

0.68

(0.64)

0.278

Baseline CAT scorea

 

13.17

(7.95)

16.45

(9.54)

13.78

(7.86)

20.06

(7.86)

< 0.0001

Exacerbations

 Severeb

0.2

(0.6)

0.44

(1.62)

0.31

(0.82)

1.25

(2.27)

< 0.0001

 Totalc

0.49

(1.19)

1.09

(3.39)

0.92

(2.14)

2.09

(2.91)

< 0.0001

 Total at baselined

0.25

(0.68)

0.58

(1.39)

0.22

(0.63)

0.62

(0.99)

0.011

Activity limitation

 6-min walk distance (m)

445.66 (91.31)

386.64 (136.27)

420.38 (71.19)

385.16 (94.09)

0.0003

 Oxygen desaturation with 6-min walk (%)

14

36

14

41

< 0.0001

  1. Biomarkers data for 5 subjects were not available. Kruskal-Wallis and chi-square tests were performed for continuous and categorical variables, respectively. aCAT score range from 0 to 40, with higher scores indicating greater severity symptoms. bTotal count of exacerbations requiring ED visit or hospitalization since entering the study. cTotal count of exacerbations since entering the study. dTotal Exacerbations for baseline